Impacts Of Oil On Sea Turtles - Sea Turtles and Oil Spills

Impacts Of Oil On Sea Turtles - Sea Turtles and Oil Spills Oil spills can be devastating for a variety of marine life, especially for endangered species like sea turtles.   There are 7 species of sea turtles, and all are endangered. Sea turtles are animals that travel widely, sometimes thousands of miles. They also use the shorelines, crawling up onto beaches to lay their eggs. Because of their endangered status and their wide range, sea turtles are species that are of particular concern in an oil spill. There are several ways that oil can impact sea turtles. How Do Oil Spills Effect Sea Turtles? Ingestion of Oil or Oil-Contaminated Prey: Turtles dont tend to avoid oil spill areas, and may continue to feed in these areas. They may eat oil or prey that has been contaminated by oil, resulting in a number of complications for the turtle. These can include bleeding, ulcers, inflammation of the gastrointestinal system, problems with digestion, damage to internal organs, and overall effects on the immune and reproductive systems. External Effects From Swimming in Oil: Swimming in oil can be dangerous for a turtle. Breathing vapors from the oil can result in injury (see below). Oil on the turtles skin may result in skin and eye problems and increased potential for infection. Turtles can also suffer burns to their mucous membranes in the eyes and mouth. Inhalation of Oil Vapors: Sea turtles must come to the ocean surface to breathe. When they come to the surface in or near an oil spill, they may breathe toxic fumes from the oil. Fumes may result in irritation of the turtles eyes or mouth, and internal damage such as irritation to the respiratory system, injured tissues or pneumonia. Impacts On Sea Turtle Nesting: Sea turtles nest on beaches - crawling up on the beach and digging holes for their eggs. They lay their eggs, and then cover them up, until the turtles hatch and the hatchlings make their way to the seas. Oil on beaches may affect the health of the eggs and the hatchlings, leading to a lower hatchling survival rate. What Can Be Done? If affected turtles are found and collected, they can be rehabilitated. In the case of the Gulf of Mexico oil spill, turtles are being rehabilitated at 4 facilities (1 in Louisiana, 1 in Mississippi, and 2 in Florida). More Information on Oil Spills and Sea Turtles: Louisiana Marine Mammal and Sea Turtle Rescue Program. Accessed June 10, 2010.NOAA. 2010.  Sea Turtle Strandings and the Deepwater Oil Spill  (Online). NOAA. Accessed June 10, 2010.

Same-Gender Adoption essays

Same-Gender Adoption essays Imagine youre a couple, deeply in love, committed to each other for life and desperately wanting children, only you cant have any. Why? Not because of what the average person might think. Its because youre a gay or lesbian couple, or, as many that are of the persuasion prefer to call it, same-gender couple. In todays world, where we are considered to be in an enlightened society, same-gender couples not only encounter the usual barriers because they want to be together, but its even worse when trying to fulfill their dreams of having children. There are legal issues surrounding same-gender adoption, as well as moral issues. With so many children looking for loving parents throughout the world, one might ask why NOT allow same-gender couples to adopt them. In an article written by Sean Cahill, all of the candidates for President in 2000 were asked where they stood on this issue. George W. Bush opposes gay men and lesbians serving as adoptive parents. When he was governor of Texas, he supported a bill which would bar gays and lesbians from adopting. He is quoted as saying Im against gay adoptions. I believe children ought to be adopted in families with a woman and a man who are married. Society ought to aim for the ideal, and the ideal is for a man and woman to adopt children (Cahill 25-26). In this same article, Al Gore states: We have a huge number of children who cannot find adoptive parents. Local adoption officials can evaluate the circumstances of the child and the parenting ability of prospective parents and decide if theres a good match. Gores spokesperson said that the vice president would leave gay adoptions up to adoption professionals on an individual basis (26). In a study at the Catholic University of America, the Marriage Law Project was conducted examining same-gender adoption f...

Pharmaceutical Industry in India Essays

Pharmaceutical Industry in India Essays Pharmaceutical Industry in India Essay Pharmaceutical Industry in India Essay Industry overview Pharmaceutical sector is an important industry of any modern day economic power. Pharmaceutical industry in India has a very humble past. After independence, development of pharmaceutical industry was one of the top agenda of government along with steel and manufacturing industry. The market was protected against competition for a long period of time by giving incentives to small firms, license-raj etc. Today the Indian pharmaceutical industry is the front-runner science-based industries in the country. Today the industry boasts of wide ranging capabilities in the complex field of drug manufacture and technology. The sector is pegged to be worth US$ 7. 3 billion. The annual growth rate is estimated to be around 13%. Reports suggest that the domestic retail market would be worth around US$ 12 billion by 2012. Indian pharmaceutical industry ranks 4th in terms of volume globally and 13th in terms of value. It has 8% share in global sales 20%-24% share in production of generic drugs. The domestic players satisfy almost all of the country’s demand for formulations and bulk drugs. Indian firms aren’t limited to domestic market; they are now competing head on with multi national players in international arena. For many firms, exports constitute 60%-70% of the total revenue earned. Reasons for this strong growth are low cost of manufacturing, low cost of RD, innovative scientific manpower etc. The total pharmaceutical exports in 2007-08 clocked US$ 6. 68 billion against US$ 5. 73 billion in 2006-07 recording a growth rate of 16 per cent. India is poised to be one of the fastest growing pharmaceutical markets in the world. This has led to entry of many major companies in the Indian market and a huge amount of FDI inflow. Evolution of the Indian Pharmaceutical Industry The Indian regulatory system made several arrangements to protect the domestic pharmaceutical industry from foreign competition in its nascent phase. One of them was recognition of only process patents. This built a sound and strong base for strong and competitive domestic market but deterred entry of foreign players. The life of Indian pharmaceutical industry can be broadly divided into two phases, namely Pre-Patent regime and Post-Patent regime respectively. Lets take a look at both of them in detail: Pre-Patent Regime: This period can be segmented into various time periods for better understanding: 1947-1970 During this period country was trying to stand on its feet after gaining independence. The pharmaceutical industry had to be built from scratch. Though several domestic players had sprung up in market but their impact on market was limited. The reason was their inability to compete with MNC players who had better access to resources, better technical know how and access to larger amount of funds. These foreign players imported formulations and sold them in India. They were neither contributing to pharmaceutical industries nor to the manufacturing industries in India. People had low spending and restricted access to healthcare facilities because of low levels of income. The government had realized that dependence on imported drugs had to be reduced so that essential drugs could be made available to public at cheap prices. For this country needed to build indigenous drug production capabilities. To fulfill this objective Hindustan Antibiotics Limited (HAL) and Indian Drugs Pharmaceutical Limited (IDPL) were setup in 1954 and 1961 respectively. These companies soon established themselves as major producers of critical drugs, which, were being imported at that time. 1970-1979 The MNCs continued to dominate the domestic market in spite of steps taken by government. Government introduced two legislations in 1970 to accelerate the process of self-reliance and indigenization. These were Indian Patent Act and Drug Price Control Order (DPCO). These two regulations provided the launch pad for the Indian pharmaceutical industry to take off into a new growth spiral. Indian Patent Act: The act granted patents only for methods and processes used to manufacture the substance. This allowed the domestic players to reverse engineer the drugs present in market and find its constituents. They started making the product using the same bulk drug by using a modified production process. Drug Price Control Order: Government regulated prices of 354 essential bulk drugs and formulations to ensure wide spread availability of drugs at a reasonable price. These two legislations changed the industry structure and growth pattern. Several small-scale ndustries (SSI) came into existence in formulation business. They had significant advantage as their products were out of purview of price control. Low entry barriers, abundance of bulk drugs and dispersed market acted as additional catalysts. All these factors had a significant impact on the position of MNCs in India. These regulations introduced the concept of price control did not recognize product patents. Therefor e the MNCs had no incentive of introducing new drugs in the market. Their overall share in formulations started to decline as time progressed. 1979-1987 Government in 1979 amended DPCO. Number of drugs under purview of DPCO was bought down from 354 to 163. Government also increased the permissible mark-up on drugs from 40%-60% to 75%-100%. DPCO also regulated the production by fixing ratio between formulation and key bulk drugs. This ensured continuous and uninterrupted supply of key bulk drugs. Investments made by government in past had started bearing fruit. IDPL and HAL provided technical assistance to smaller players in establishing their foothold. Hence even smaller players started to supply critical drugs to market. Indian firms started to invest in RD because of availability of skilled researchers in country. This resulted in launch of new drugs through process re-engineering. Government funded Central Drug Research Institute (CDRI) and Council of Scientific and Industrial Research (CSIR) made major contribution to the research base. Indian firms had advantage of low cost structure and very good reverse engineering technical skills. After they had established themselves in domestic market they turned their attention towards export. They took measures to utilize their advantage in global arena and were quite successful. There was no improvement in conditions of MNC’s. High tariffs caused the prices of their product to go up. Price control measures taken by government directed them to sell at cheaper price. Therefore they focused on specific sectors where they still had a stronghold. They were reluctant to launch new products in country because of lack of proper patent protection. This resulted in overall decline of their market share. 1987-1994 This was a consolidation period of the industry. The entire industry registered a double-digit growth rate through the period. This high growth rate was attributed to rise in per-capita income of people and introduction of new drugs at cheap price. The increase wasn’t limited to domestic market. While bulk drug production grew at CAGR of 16%, bulk drug export grew at CAGR of 40%. By 1994 exports comprised 50% of total bulk drug production. To meet the ever-increasing demand, companies had to invest heavily in increasing their capacities. High growth rate also attracted new players to the market. Competition in market increased manifold as the number of players in the market doubled over this period. Most important development of this period was liberalization program initiated by the government. The tariff barriers were lowered which leveled the playing field for MNCs vis-a-vis domestic players. This also increased foreign investment in domestic pharmaceutical industry. The liberalization policy also benefited domestic players who made efforts to increase their global presence due to lower tariff and non-tariff barriers. 1995-2001 The major development of this phase was government’s commitment to recognize product patent regime after 2005. This increased the expectation of MNCs. Most of them increased their equity stakes in Indian operations. MNCs also realized that they could convert India into their manufacturing base. India had quality manufacturing facilities at cheap costs. Domestic firms too had saturated Indian market. They were focusing on global markets more seriously now. They entered into alliances with MNCs, entered into JV’s in overseas market, set up world-class manufacturing facilities and strengthened their brands to strengthen their position. The small players finally came of age and gave serious competition to their bigger counterparts. Even though market grew at 15% intense competition from smaller players pushed the bigger players towards generic formulations. Bulk drugs had lower margins because of intense competition. To overcome this most players forward-integrated into formulation manufacturing or increased their export to non-regulated markets where margins were higher. 2001-2004 During this period domestic players increased their focus on market of generic drugs. They invested in RD and upgraded their manufacturing facilities to comply with GMP norms. During this period the domestic formulations market registered a decline, barring a few segments. MNCs were strengthening their interest in domestic market as product patent regime was to be implemented in 2005. Post-Patent Regime 2005-2006 Government passed an ordinance in 2005 implementing the product-patent regime. This move was aimed at bringing India at par with global pharmaceutical market. Other major developments during this period were implementation of VAT, shift in excise duty levy to MRP based levy and implementation of good manufacturing processes. During this period Indian players established themselves in global market with their innovatively engineered generic drugs API. 2006-2007 The new pharmaceutical policy has been center of attraction. Government wanted to bring essential drugs on which the manufacturers made fat profits under the purview of DPCO. The proposed pharmaceutical policy was aimed at bringing 354 essential drugs under purview of DPCO so that they are within reach of common man. The policy has provision of limiting MAPE to 150% to put a cap on profits earned by pharmaceutical firms. The duties on API were reduced to encourage manufacturing. Government has also set up NPPA to regulate pricing of drugs in India. Companies will have to sell their drugs at price decided by NPPA. Regulatory Environments in various parts of the world Europe The European Medicines Agency (EMEA) is the apex body, which governs medicine industry in Europe. Scientific opinions of the agency are prepared by committees i. e. the committee for medicinal products for human use (CHMP), the committee for medicinal products for veterinary use (CVMP), the committee for orphan medicinal products for rare diseases (COMP) and the new committee on herbal medicinal products (HMPC). EMEA performs the scientific evaluation of the quality, safety and efficacy of medicinal products in EU. EMEA also coordinates the resources for scientific evaluation and assessment regarding products undergoing the mutual recognition procedure and the master files for plasma and vaccine antigens. EMEA also provides guidance for companies requesting scientific advice. It also provides scientific advice before the application of new marketing authorization for centralized and mutual recognition procedures. Scientific Advice Working Party (SAWP) does this task. In order to sell products in EU markets firm have to obtain a license. This license is granted by CHMP after it assesses the product in question. European Pharmacopoeia (Ph Eur) specifies the quality specifications for pharmaceutical preparations and their ingredients. Before submitting a Marketing Authorization Application (MAA) the firm is required to show the safety and efficacy of the medicinal product. To show this local clinical data should be generated for a new medicinal product. Thus it is necessary to conduct clinical trails before launching a product in EU. If the product has already proved safety and efficacy in some other country then a bridging clinical study is sufficient. The initial license granted to a firm has to be renewed after five years. The risk-benefit balance is revaluated. If the result of re-evaluation is positive then the firm is granted the license for unlimited period of time unless the competent authority decides otherwise. In cases of drugs that require long-term safety study, the license for unlimited period is usually granted after 2-3 re-evaluations. The EU pharmaceutical legislation is very extensive and robust. In order to ensure high quality and safe therapies it provides extensive rules and guidance on licensing procedures for medicinal products. USA Pharmaceutical sector in USA is regulated by the department of Health and Human Services. The apex regulatory body is US FDA, which enforces the basic drug and food legislations. When a drug manufacturer develops a new drug, first the drug is tested on animals. Then he obtains approval for human trials through Investigational New Drug (IND). The data collected through human clinical trials in IND and animal studies is used to file a New Drug Application (NDA). NDA is used to communicate to FDA about safety and effectiveness of the drug, high quality manufacturing standard for the drug and appropriate labeling of the drug. New drugs are developed under patent protection. This grants exclusive marketing rights to the developer of the drug. After expiry of the patent period, other firms can sell a copy of the drug. This copied version of drug is called as generic drug. In order to get approval from FDA to sell generic drugs, firms must file for an Abbreviated New Drug Application (ANDA). Generic drug sector became very lucrative because the manufacturers of generic drugs didn’t have to invest in costly animal studies and human clinical trials. Also the pharmacists were given the right to sell substitute generic drugs instead of a specific drug unless explicitly specified by the doctor. To get an FDA approval for their ANDA the firms had to ensure that their drugs contains the same amount of active ingredient as the original drug, it should be identical in dosage form, strength and administration method and manufactured under the same manufacturing standards as for the original drug. A Drug Master File (DMF) is submitted to FDA that contains almost all information related o the drug. Some information in the file may be of confidential nature. India In India both the central government and the state government share the responsibility of regulating the pharmaceutical industry. The Drug and Cosmetic Act and Drug and Cosmetic Rule are the legislations passed by the government in this regard. Through this legislation the government regulates import, manufacture, sale and distribution of drugs in India. The central government plays as the coordinator of policies like drug approval, clinical trials, setting up standards, controlling the quality of imported drugs etc where as the state governments see that the policies laid down by the central government are being implemented by the firms. The Drug Controller General of India (DCGI) co-ordinates all the activities involved. Pharmaceutical industry in India regulated on basis of price, patent quality. DPCO fixes an upper limit on critical formulations API. NPPA regulates the pricing of all the drugs manufactured or sold in India. A firm cannot price its drug on its own; it has to be approved by NPPA. NPPA has also put an upper limit of 150% on MAPE. If the firm invests heavily in RD then the limit is increased by 50%. In 1995 government had amended DPCO to limit the size of drugs under purview of DPCO to 74. After implementation of product patent regime government is mulling over bringing the number of drugs under DPCO to around 200. The Drug Cosmetic act specifies the quality standards to be met for any drugs that is manufactured, sold or distributed in India. Manufactures have to follow GMP in their manufacturing plants. FDI up to 74% is allowed on the automatic route in the case of bulk drugs, their intermediate Pharmaceuticals and formulations (except those produced by the use of recombinant DNA technology). The Government considers FDI above 74% for manufacture of bulk drugs on a case-by-case basis. It’s allowed only for manufacture of bulk drugs from basic stages and their intermediates. It also extends to bulk drugs produced by the use of recombinant DNA technology and the specific cell/tissue targeted formulations if it includes manufacturing from basic stage. Government had liberalization plans of increasing the FDI cap to 100% and making the process of investing more easily and investor friendly. The plans were not implemented because of political pressure exerted by the Left Parties on the government. Recent Developments Raw material shortage hits pharmaceutical firms Olympic games in China have put brakes on high-flying Indian pharmaceutical industry. In order to present its clean image before the world during the games, China has ordered to close various drug manufacturing units to prevent environmental degradation. This has caused a scarcity of raw material in India and has pushed up prices of generic medicines. Daiichi Sankyo buys majority stake in Ranbaxy Daiichi Sankyo Company, Ltd (Daiichi Sankyo) has bought majority stake in Ranbaxy Laboratories Limited (Ranbaxy) from the Singh family, the largest controlling shareholders of Ranbaxy. The deal is subject to regulatory approvals. This deal will allow Ranbaxy access to global markets that have been off-radar for the firm till now. Daiichi Sankyo is looking forward to gain a stronger foothold in a very fast developing Indian market as well as the base established by Ranbaxy in USA. Sun Pharmaceuticals gets USFDA nod for generic Depakote The USFDA has granted a final approval to Sun Pharmaceutical Industries Ltd for its Abbreviated New Drug Application (ANDA) for generic Depakote, divalproex sodium delayed release tablets. Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures. US Congress to probe FDA`s Ranbaxy case The US House Energy Commerce committee is investigating the FDAs stance on the Ranbaxy case. The committee is to probe FDAs handling on Ranbaxys imports. The committee will also probe whether FDA knowingly let unsafe medicine to enter US. Sun Pharmaceuticals Taro deal Sun Pharmaceuticals, offered $454 million, all in cash, to buy out an Israeli generics manufacturer, Taro Pharmaceuticals. The deal has not been completed as yet because of encountering several roadblocks. Taro Pharmaceuticals is an Israeli pharmaceutical firm with a global presence. By acquiring Taro, Sun is trying to enter the low-competition, specialized segments like dermatology and pediatrics. Taro’s large presence in the Canadian market is also an attraction for Sun. Key Features of quarter April-June FY09 Improvement in product and geographic mix: Higher contribution from exports (62%) for generics and higher proportion of CRAMS business (46%) were the key highlights of the quarter. Improvement in margins: led by higher overseas and CRAMS sales, a 5. 9% YoY depreciation in the Rupee v/s the USD and increased captive consumption from companies like Dishman, Lupin and Piramal Healthcare. Raw material pressure to persist in the near term: China’s decision to (i) shut down polluting plants around Beijing and (ii) restrict the movement of hazardous chemicals in view of the Olympics resulted in raw material shortages and a consequent increase in prices. A rise in crude oil prices resulted in increases in the price of API solvents and intermediates. Our interaction with a few companies suggests that raw material shortage may persist for the next one-two quarters. Depreciating rupee leads to MTM losses on Forex debt: A 7. % and 9% QoQ depreciation of the rupee v/s the USD and Euro respectively resulted in most companies declaring MTM losses on their FCCBs and foreign debt. Prominent among the losers were Ranbaxy, Jubilant and Cipla. GSK recently signed a deal with Aspen and Strides GSK Pharmaceutical has collaborated with Aspen through which it would have access to a portfolio comprising 1200 products and 450 molecules of Aspen and its JV with Strides. GSK would get these products approved in 95 emerging markets and distribute and market these as well, while Aspen will continue to market in Sub-Saharan Africa and other countries. Jubilant signs drug discovery pact with Amgen Jubilant Bosys Ltd. and Amgen Inc. , the largest US-based biotech company on Monday announced a drug discovery partnership. As per the deal, Amgen and Jubilant will collaborate to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas. Jubilant will develop early preclinical candidates emanating from Amgens early discovery efforts for an initial term of three years. Amgen will have responsibility for the subsequent pre-clinical and clinical development and commercialization. Amgen will retain / own the drugs developed under the collaboration with worldwide commercialization rights. Jubilant Biosys will partner in early-preclinical development effort from its state of the art Jubilant Research Centre Bangalore, while Amgen will pursue later stage pre-clinical and clinical development and commercialization of the drugs in global markets. The financial terms include a combination of research funding and success-based milestones paid to Jubilant during pre-clinical and clinical development for multiple projects undertaken by the collaboration. The total financial Milestone value is subject to successful development and commercialization of the portfolio of novel drugs. Glenmark`s molecule for Neuropathetic Pain to enter Phase I trials Glenmark Pharmaceuticals Ltd has announced that its candidate for Neuropathic Pain, Osteoarthritis and other Inflammatory Pain-GRC 10693 is entering Phase I trials. The company intends to develop GRC 10693, a cannabinoid-2 (CB-2) receptor agonist, in neuropathic pain as the primary indication. The molecule has been filed for Phase-I approval with European regulatory authorities. Biocon, Abraxis launches ABRAXANE in India Biocon Limited and Abraxis BioScience, Inc, a fully integrated biotechnology company announced the launch of ABRAXANE (paclitaxel protein bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy, ABRAXANE is now available in India as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). The Phase III clinical trial in the U. S. demonstrated that ABRAXANE nearly doubled the response rate, significantly prolonged time to progression, and significantly improved overall survival in the secon line setting versus solvent based Taxol in the approved indication. The Medical House ties up with Dr Reddys Labs The Medical House Plc, a drug delivery specialist has signed a non-exclusive development, licensing and supply agreement with Dr Reddys Laboratories. The agreement covers an initial five-year term of supply, within US, European Union and Canada, with an option for Dr Reddys to extend the agreement to the rest of the world, on mutually agreed terms, the company said in a filing to the London Stock Exchange. The duration of the agreement can also be extended by mutual agreement and the development costs associated with customization would be paid to The Medical House (TMH) in addition to reimbursement of all agreed external costs. Strides completes acquisition of Ascent Pharmahealth Strides Arcolab has completed the acquisition of controlling interest in Ascent Pharmahealth Limited (formerly Genepharm Australasia Limited), thereby making Strides the 4th largest Generics Company in Australia. Strides now holds 50. 1% stake in Ascent Pharmahealth Limited, an ASX listed company. At final closing in Sept ’08, Strides may own upto 55% in Ascent Pharmahealth Ltd. Shareholders have voted to change the name of Genepharm Australasia Limited to Ascent Pharmahealth Limited. Ascent Pharmahealth Limited will include the assets of Drug Houses of Australia [DHA] in Singapore, a wholly owned subsidiary of Strides Revenue in excess of US$90mn on a combined Performa basis. Lupin acquires Hormosan Pharma Lupin Ltd has acquired Hormosan Pharma GmbH (Hormosan), a German Sales and Marketing generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS). Hormosan, with total sales of Euro 6. 8mn for the year ended December 2007, develops, licenses and markets a range of generics in Germany. Hormosan has a complementary product portfolio with products in the Central Nervous System and Cardiovascular therapeutic segments. Hormosan has created a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector. Besides strong key account management the company also has a successful in Regulatory team, Pharmacovigilance, Medical Information and Marketing teams. Aurobindo Pharma receives nod for 2 ANDAs Aurobindo Pharma has received final approval from the US Food Drug Administration (USFDA) for 2 ANDAs namely Ceftriaxone for injection USP 250mg, 500mg, 2g and Ceftriaxone for injection USP 10g pharmacy bulk pack. These are Cephalosporins under the Anti-infective segment. Lupin Pharma receives nod for Divaiproex. Sodium Tablets Lupin Pharmaceuticals, Inc. (LPI) has received final approval for the Companys Abbreviated New Drug Application (ANDA) for Divaiproex Sodium Delayed-Release Tablets, 125 mg, 250 mg and 500 mg from the U. S. Food and Drug Administration (USFDA). Commercial shipments of the product have already commenced. Lupin Divaiproex sodium delayed-release tablets are the AB-rated generic equivalent of Abbott Laboratories Depakote tablets. Depakote had annual sales of approximately US$ 803mn for the twelve months ended March 2008, based on IMS Health sales data. Dr Reddy`s lab to invest in Perlecan Pharma Dr Reddys lab has purchased holding of Citigroup Venture Capital International Mauritius Limited its nominees and IDBI Trusteeship Services Limited (the merged entity after its merger with The Western India Trustee and the Executor Company Limited) in Perlecan Pharma Private Limited. The Board of Directors of Dr Reddys Laboratories Limited at their meeting held on July 21, 2008 had approved this proposal aggregating to US$18mn. References: pharmaceutical-drug-manufacturers. com/pharmaceutical-industry/ thehindubusinessline. com/iw/2004/07/25/stories/2004072500401000. htm ibef. org/industry/pharmaceuticals. aspx www. indiainbusiness. nic. in/industry-infrastructure/industrial-sectors/drug-pharma. htm

Semantic Web Essay Example | Topics and Well Written Essays - 2500 words

Semantic Web - Essay Example It may be said that these systems contained limited amount of research material. Rather than storing in cupboards, papers and books were stored in machines, which definitely improved the research strategy. It laid the basis of what we know as ‘Web’ today. With the advancement in technology, and initiation of internet, the landscape of research tools began to change. Late 1990’s is registered with some remarkable changes in the techniques of research tools (Baker & Cheung, 2007). In 2001, the introduction of ‘Web’ revolutionized the conventional ways of research. This initial Web design served as the storage of billion of documents. Researchers were allowed to access their desired content, and read it. This made Web an advance form of library. The first version of the World Wide Web, Web 1.0 facilitated the users to search ‘online library’ to the extent of reading only. The speed was fast, and the technology was new, so it got popular very quickly. The need of improvement was felt when the technology started revolutionizing, and access was limited. The updated version of web, Web 2.0, brought some drastic changes in the web research tools. It promoted human interaction with web. Now the Web did not serve the purpose of a just a library, but it became an interactive tool where people were allowed to alter the research content. The Web stuff was not a read-only material, but it also allowed users to make changes, write their own papers. It was the change that was instantly felt by the users. This laid the basis of the social networking. The Semantic Web is the next generation of the Web, which attempts a precise automatic filtering of information. For this, it is necessary to make the information that resides on the Web which is understandable by the machines. With this, we can determine that the Semantic Web is about different fields, first is a set of languages and procedures to add the semantics to information that is understandable by the

Business at the Base of the Pyramid Essay Example | Topics and Well Written Essays - 1750 words

Business at the Base of the Pyramid - Essay Example 4). Survival for companies, at the base of the pyramid, directly hinges on the level of innovation that is put into the products (Prahaland 2002, p. 5). Achieving new levels of capital efficiency is a pre-requisite to profitable operation at the base of the pyramid (The European Alliance 2008, p. 11). The emphasis of business structure remodeling should be to produce innovative product using innovative means. This in turn necessitates the need to adopt innovative manufacturing processes. The guiding principle that should be adopted is the production of commodities that aid the community in meeting its development objectives (The European Alliance 2008, p. 10). The simple fact is that positioning a product to enhance the lives of the poor has a variety of advantages, chief of which is the financial advantages that will accrues from this approach (London 2007, P.9). The approach that should be adopted by the firms, which focus on the bottom of the pyramid, should entail employing an in novative manufacturing process, which will reduce the overall cost of production. This is in line with the fact that operating at the bottom of the pyramid entails lowering of prices and repackaging products into financially friendly units. This is best exemplified by the approach adopted by HLL India (Prahaland 2002, p. 6). The firm launched a new product called Wheel which essentially reduced the ration of oil to water in their detergent. When this was coupled with the low cost pricing strategy that they had set up, the result was a booming product which appealed to the poor consumer. This then ushers in the point of distribution. In order to target, effectively, the bottom of the pyramid, there must be systems that have been put in place, to ensure that the distribution mechanisms are able to access, effectively, the poor people (Prahaland 2002, p. 5). The lack of equitable wealth distribution restricts the poor to the sidelines of the global economy. This is regardless of the ve rity that they comprise a significant portion of the population. The status and nature of the poor makes it extremely difficult to reach via the conventional models that have reigned supreme using traditional business models (International Finance Corporation 2007, p. 3). The appropriate structure should be to position sales points to the small outlets, which are frequently used by the poor. These small outlets are characteristics of the dwellings of the poor. As such, should constitute as sales points for the business models of the bottom of the pyramid. Efficient distribution systems have greater potential of providing to large and untapped market. The largest being sourced from the rural poor. As such, with models that encompass structuring distribution points in the rural areas are better placed to tap these large and exponentially growing markets (Schrader, Freimann and Seuring 2012, p. 289). This is best done by structuring the business model to bring the product closer to the customer (The European Alliance 2008, p. 13). This in turn ushers in the need to check on the infrastructure. As such, this necessitates the need to incorporate NGOs and the government into a mutually benefitting partnership (The European Alliance 2008, p. 10). Aside from this, another vital aspect, to take into consideration is

DNA Practical Lab Report Example | Topics and Well Written Essays - 1000 words

DNA Practical - Lab Report Example One purine pair with one Pyrimidine with hydrogen bond to make the double stranded DNA. Adenine (A) pairs with Thymine (T) with double H-bond and Guanine (G) pairs with Cytosine (C) through triple H-bond. Isolation procedure requires disruption of cells so that the cell content comes out, followed by sedimentation of the cellular debris on application of centrifugal force and to collect the DNA from the supernatant. These DNA fragments are separated using gel electrophoresis. The process encompasses separation, based on their size, the pore size of the gel, the voltage gradient applied and the salt concentration of the buffer. Larger pore size is for the separation of fragments larger than 500- 1000 bp and smaller pore of agarose gels are used to resolve fragments smaller than 1000 bps and can be visualized. The technique of electrophoresis is based on the fact that since DNA contains phosphate group, it is negatively charged at the neutral pH. When electric potential is applied, it moves towards the positive terminal. The solidified agarose gel is inserted into the electrophoresis chamber and is just covered with buffer. The DNA sample is mixed with the loading buffer and then pipette in the sample wells. On application of the current DNA migrates towards positive (red colored) electrode. The distance DNA has migrated in the gel can be judged by visually monitoring migration of the tracking dyes. After adequate migration, DNA fragments are visualized by ethidium bromide. This is a fluorescent dye and it intercalates between the bases of DNA and RNA. It is incorporated in the gel so that staining occurs during electrophoresis. Bands appear on the gel and can be visualized. Results: Part 1 A fluffy white layer was formed at the boundary between the green and the purple liquids when the ethanol was added. It was made up of fine filaments. Part 2 After putting the electrical current, strands of the DNA become visible to the naked eye. It becomes like stains, or bands, on the gel. Discussion NaCl removes protein and carbohydrate in DNA and also act as lysing buffer. NaCl contains Na+ which binds with the negatively charged phosphate molecule of the DNA. It also stabilizes the pH and process the density of DNA. Washing liquid reduces the acidity of solution and remove CO2. Detergents remove the interfering cells and are used as a substitute for the chemical compound that is capable of damaging the cell wall and membrane. They act as emulsifying agents and can digest compound that causes stiffness of polymeric cells. Endiamin tetra ethyl acetate (EDTA) serves to remove the Mg+2 ion and proven enzymes which can damage cellular DNA, it protects the DNA from DNAse. It interrupts the interaction of polar cell membrane and unites as detergent. Gel electrophoresis is a powerful tool for the separation of macromolecules with different sizes and charges. DNA molecules have an essentially constant charge per unit mass thus they separate in agarose, based on the size, smaller the size more distance it can travel and larger the size of the DNA less it can travel. Increasing the concentration of a gel reduces the migration speed and enables separation of smaller DNA molecules. The

Monster Assignment Example | Topics and Well Written Essays - 250 words

Monster - Assignment Example Battleground mentality monster explains that leaders engage in battleground images during business operations; for instance, aggressive marketing campaigns to completely eliminate competitors. Functional atheism illustrates that leaders assume that they possess ultimate or final responsibility in all decisions or operations of the organization. The fear monster of the leaders emphasizes bureaucracy instead of innovation and creativity. Organization stakeholders operate strictly within established procedures and rules. Denying death monster allows the leaders to ignore negative organization issues like the collapse of a project. The evil monster illustrates the inner darkness of the leader; for instance, the fear of delegating responsibilities to junior staffs. This is because the junior staffs may outperform the leader (Craig, 2015). The monster that produces most harm in the organization is the functional atheism. The leader believes that he/she is responsible for all significant decisions. This limits the ability of employees to participate in the organizational decision making process. At the workplace, this monster is recognized through the inability of the leader to delegate responsibility tasks and authority to the immediate subordinates. The effect of this monster can be minimized through encouraging employees and managers to work in the same team or task forces. Teamwork encourages sharing of ideas and hence improves overall organizational